Wellington Management Group LLP Has $3.73 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Wellington Management Group LLP decreased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 83.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,157 shares of the biopharmaceutical company's stock after selling 332,624 shares during the quarter. Wellington Management Group LLP owned approximately 0.05% of Halozyme Therapeutics worth $3,730,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HALO. International Assets Investment Management LLC acquired a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $33,000. GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 350 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at $49,000. Toth Financial Advisory Corp bought a new position in Halozyme Therapeutics during the 3rd quarter worth $57,000. Finally, FSC Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth $65,000. 97.79% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on HALO shares. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and upped their price target for the company from $58.00 to $62.00 in a research note on Monday, October 7th. HC Wainwright restated a "buy" rating and set a $68.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research report on Friday, November 1st. Piper Sandler boosted their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a "neutral" rating in a research note on Monday, November 4th. Finally, JPMorgan Chase & Co. lowered Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and raised their price objective for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $61.11.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $56.34, for a total transaction of $563,400.00. Following the completion of the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $38,127,756.96. This represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 30,000 shares of company stock worth $1,621,800 over the last 90 days. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Price Performance

Shares of HALO traded down $1.76 during midday trading on Wednesday, hitting $46.84. The company's stock had a trading volume of 1,849,963 shares, compared to its average volume of 1,363,617. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The stock has a market capitalization of $5.96 billion, a price-to-earnings ratio of 15.51, a price-to-earnings-growth ratio of 0.43 and a beta of 1.23. The company's fifty day simple moving average is $51.20 and its two-hundred day simple moving average is $54.14.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.